MARKET

EVOK

EVOK

Evoke Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.660
+0.050
+3.11%
Closed 16:00 12/06 EST
OPEN
1.570
PREV CLOSE
1.610
HIGH
1.690
LOW
1.570
VOLUME
308.20K
TURNOVER
--
52 WEEK HIGH
3.260
52 WEEK LOW
0.5001
MARKET CAP
40.22M
P/E (TTM)
-4.4648
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of EVOK and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

EVOK News

  • Evoke Pharma Regains Compliance with Nasdaq Minimum Bid Requirement
  • GlobeNewswire.4d ago
  • Evoke Pharma up 32%
  • Seeking Alpha - Article.11/18 20:50
  • What Kind Of Shareholder Appears On The Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shareholder Register?
  • Simply Wall St..11/18 13:52
  • Evoke Pharma Granted 180-Day Extension by Nasdaq Regarding Minimum Bid Price
  • GlobeNewswire.11/13 13:30

More

Industry

Pharmaceuticals
+0.53%
Pharmaceuticals & Medical Research
+0.68%

Hot Stocks

Name
Price
%Change

About EVOK

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.
More

Webull offers Evoke Pharma Inc (EVOK) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.